Nabriva Therapeutics AG (NBRV) PT Raised to $20 at Morgan Stanley
Tweet
Share
E-mailGet Alerts NBRV Hot Sheet
Price: $1.42 --0%
Rating Summary:
4 Buy, 6 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
4 Buy, 6 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Morgan Stanley analyst David Lebowitz raised the price target on Nabriva Therapeutics AG (NASDAQ: NBRV) to $20.00 (from $2.00) while maintaining a Equalweight rating.
You May Also Be Interested In
- Fiserv (FISV) PT Lowered to $60 at Freedom Broker
- Lithium Ionic Corp (LTH:CN) PT Lowered to Cdn$2.50 at Desjardins
- Stantec Inc. (STN:CN) (STN) PT Lowered to Cdn$169 at Desjardins
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
